Alnylam Pharmaceuticals vs Royalty Pharma
ALNY and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and RPRX compare
Royalty Pharma is the larger company, worth 1.7 times as much as Alnylam Pharmaceuticals ($38.6B against $22.1B).
Royalty Pharma pays a dividend yielding 1.4%; Alnylam Pharmaceuticals does not pay one.
Royalty Pharma scores higher on the StockData Score (8 against 7 for Alnylam Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | RPRX |
|---|---|---|
| Size and price | ||
| Market cap | $22.1B | $38.6B |
| Share price | $165.00 | $67.18 |
| Change, 1 year | −65.7% | 83.2% |
| Change, 5 years | −11.9% | 70.0% |
| Beta (5Y) | 0.88 | 0.41 |
| Employees | 2,500 | 100 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | – | 38.2× |
| P/S | – | 15.2× |
| P/B | 6.1× | – |
| EV/EBITDA | – | 32.9× |
| PEG | – | 0.24 |
| Fair value | – | $45.40 |
| Margin of safety | – | −48.0% |
| Growth | ||
| Revenue growth (TTM) | – | 10.0% |
| Revenue growth, 5Y average | 49.8% (better) | 2.3% |
| Net income growth (TTM) | 2137% (better) | −20.4% |
| EPS growth (TTM) | – | −19.3% |
| EPS growth, 5Y average | – | 6.2% |
| Profitability | ||
| Operating margin | – | 59.6% |
| Net margin | – | 32.1% |
| Return on equity | 127% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 5.37 |
| Interest coverage | – | 4.2× |
| Current ratio | 2.48 | 2.80 (better) |
| Altman Z-score | 2.75 | 2.93 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Buyback yield | – | 0.83% |
| Shareholder yield | 0.00% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 99.8% | 63.8% |
| Held by insiders | 0.49% | 22.6% |
| Insider net buying, 12 months | −$43.6M (better) | −$92.6M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 5.8% | 2.9% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.